TV continues to attract pharma’s media spend: Nielsen

Share this article:
Pharmaceutical companies increased spending on network TV by 12% in 2006 compared to 2005, according to figures from Nielsen Media-Plus. The boost in network TV, to $1.8 billion last year, suggests most drug marketers’ confidence in the medium has not waned, despite reports that some companies such as Johnson & Johnson are shifting a larger portion of ad dollars into so-called non-measured media like paid search. Overall, spending in the major media consumer ad category for 2006 rose 14.9% percent over the previous year, to $5.6 billion. Other TV venues continued to draw bigger shares of pharma media budgets, including cable, up 3% to $1.4 billion; syndicated TV, up 31% to $286 million; and spot TV, up 11% to $173 million. Meanwhile, spending on Internet display ads rose 52% but still only accounted for $82 million. Rivaling the TV spend was investment in print, which increased 31% to $1.7 billion last year. As previously reported, the data also revealed: *Pfizer increased its major media consumer ad spending budget by $158 million in 2006, a jump of 32%. *Merck upped its 2006 major media consumer ad budget by $118 million, a 40% increase. *Sepracor’s major media consumer ad budgets grew by $95 million, also a 40% increase.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...